Market Performance Overview
On the trading session that closed at 12:55 AM Central Europe on Friday, 23 March 2026, Altimmune (ticker ALT) experienced a decline of 3.04 %. The closing price stood at approximately USD 2.17, a figure that matches the lowest point recorded within the past year on 16 October 2026. At the time of reporting, the company’s share supply was 194.5 million, and its market capitalization was calculated at USD 447.4 million. In the preceding 24‑hour window, trading volume totaled about USD 10 million, reflecting modest liquidity relative to the firm’s size.
The stock’s long‑term technical context shows that the 200‑day simple moving average sits at USD 3.35. The most recent peak reached USD 6.44 on 23 January 2026, while the trough of the 52‑week range coincides with the current price level. The 34.6 % decline since the close of the previous month signals a sustained downward trend, likely influenced by sector‑wide valuation pressures and investor reassessment of the company’s near‑term earnings prospects.
Comparative Peer Activity
Within the same 24‑hour period, Altimmune’s peers exhibited mixed movements:
| Company | Ticker | Daily Move | Current Price (USD) | Market Cap (USD mn) | P/E Ratio |
|---|---|---|---|---|---|
| Adtran | ADTN | +1.67 % | 6.45 | 534.5 | – |
| Tactile I | TCMD | –1.02 % | 23.55 | 532.8 | 21.82 |
| Northrim | NRIM | –0.30 % | 24.20 | 527.7 | 9.61 |
| Faeth Therapeutics | FTH | –1.06 % | 20.10 | 531.5 | – |
| Myriad Genetics | MYGN | +0.54 % | 5.76 | 529.9 | – |
Adtran and Myriad Genetics each gained modestly, while Tactile I, Northrim, and Faeth Therapeutics all reported slight declines. The relative stability of Altimmune’s peers contrasts with its sharper downward movement, underscoring the company’s specific challenges rather than a broad market swing.
Company Context
Altimmune, Inc. is a clinical‑stage biopharmaceutical enterprise headquartered in the United States and listed on the Nasdaq exchange. The firm concentrates on peptide‑based therapeutics aimed at treating conditions such as obesity, non‑alcoholic fatty liver disease (NASH), chronic hepatitis B, and other liver disorders. Its research pipeline is tailored to address unmet medical needs in these domains, and the company engages both patients and healthcare professionals across the globe. Further details are available on its public website at www.altimmune.com .
Forward Outlook
The current price trajectory, when juxtaposed with Altimmune’s 200‑day moving average and its year‑high, suggests that the market is awaiting additional data points—perhaps from ongoing clinical studies or forthcoming regulatory milestones—before reassessing the company’s valuation. Investors should monitor upcoming earnings releases, clinical trial updates, and any shifts in the competitive landscape to gauge whether the recent decline is a temporary correction or indicative of longer‑term structural adjustments.
